A reacquisition of Grail would require two developments, the first of which is a changing of the guard at the US Federal Trade Commission. This could follow a change in the occupant of the Oval Office, although I would point out that an election is also pending in the European Union, which also scotched the Illumina-Grail deal. The second main ingredient is more competition for multi-cancer early detection (MCED) tests, which is taking shape in the US despite a lack of Medicare coverage. At least some analysts seem a bit blase about the market prospects for MCEDs in the absence of coverage for those at average risk for cancer, but the sheer cost of modern cancer therapies might eventually torque that conversation in favor of population-level screening for a wide range of cancers.
Illumina’s spinoff of Grail not necessarily the final chapter #medtech @Illumina @GrailBio